Headquartered in New York, NY Fiscal year ends December NASDAQ: AXSM axsome.com
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders. It has three FDA-approved products in the U.S.:
- AUVELITY (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist for major depressive disorder in adults. It is also approved, since April 30, 2026, for agitation associated with dementia due to Alzheimer's disease.
- SUNOSI (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. It also earns royalty and milestone revenue from out-licensed territories.
- SYMBRAVO is an oral, rapidly absorbed COX-2 preferential inhibitor and 5-HT1B/1D agonist for the acute treatment of migraine, built on the company's MoSEIC rapid absorption technology.
Revenue comes mainly from net product sales in the U.S., supplemented by royalty and milestone revenue. The development pipeline spans 10 pipeline indications:
- AXS-05 in smoking cessation (Phase 3 SUMMIT)
- Solriamfetol in pediatric and adolescent ADHD, binge eating disorder, shift work disorder, and MDD with excessive daytime sleepiness
- AXS-12 (reboxetine) for cataplexy in narcolepsy, under FDA review with a May 1, 2027 PDUFA date
- AXS-14 (esreboxetine) for fibromyalgia
- AXS-17, a GABAA α2,3 positive allosteric modulator, for epilepsy
- AXS-20 (balipodect), a PDE10A inhibitor, for schizophrenia Updated
Axsome just crossed a $1 billion annual revenue run rate, powered by Auvelity after April's Alzheimer's agitation label expansion. The loss per share came in better than expectations, and management says existing cash funds operations all the way to cash flow positivity.
1,301 companies report next week, and Monday alone front-loads the read on consumer, travel and chips before the open: Estée Lauder, Marriott, Fox, Check Point and Tower Semiconductor. With misses getting punished harder than usual this season, positioning ahead of Monday morning matters.
Oversold shares of Nike (NYSE: NKE | NKE Price Prediction) are on the run. All on news that CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that…
Axsome Therapeutics is a commercial-stage biopharmaceutical company focused on central nervous system (CNS) disorders. It has three FDA-approved products in the U.S.: - AUVELITY (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist for major depressive disorder in adults.
The Wall Street consensus 12-month price target for AXSM is $265.86. AXSM price prediction →
